Biotechnology Seattle, USA-based cell therapy company Immusoft has signed a research collaboration and license option agreement with Japan’s Takeda Pharmaceutical to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system (CNS) manifestations and complications using Immusoft’s Immune System Programming (ISP) technology platform, which modifies a patient’s B cells and instructs the cells to deliver gene-encoded therapies. 18 October 2021